Three major reviews commissioned by the World Health Organization find that GLP-1 drugs including tirzepatide (sold as Mounjaro and Zepbound), semaglutide (Ozempic and Wegovy), and liraglutide ...

Dr Ellen Fallows answers key questions on the prescribing of medications for weight loss in patients with obesity ...

The company is counting on demand for obesity medicines as it expands a pipeline that includes copycat versions of Novo Nordisk's Wegovy, whose patent for semaglutide in a few markets expires in 2026.

Biocon, an Indian pharmaceutical firm, is planning a global launch of generic weight-loss drugs, aiming for high double-digit percentage revenue growth.

Researchers have discovered that drugs like Ozempic for diabetes and obesity also improve alcohol use disorders and other ...

Overweight individuals often struggle for years to lose weight. The problem: Even if a diet is successful, maintaining the achieved weight is challenging. A Danish study examined four different ...

Biocon aims for growth through new biosimilar launches and expanded insulin capacity, projecting significant revenue contributions from key products.

Biocon Ltd.’s December quarter net profit rose 475 percent to Rs.144 crore in Q3FY26 from Rs.25 crore a year earlier, primarily by lower exceptional losses, compared with the prior year, alongside ...

More than 1.6 million adults in ­England, Wales and Scotland used weight-loss drugs such as Wegovy and Mounjaro between early 2024 and early 2025.

The Bengaluru-based company on 14 January said it raised $460 million via a QIP of shares to buy out Mylan Inc’s (Viatris) stake in its arm Biocon Biologics. Days later, it announced the acquisition ...

GLP-1 receptor agonists offer more than weight loss for patients with inflammatory bowel disease, with markedly improved ...

THE number of people taking “fat jabs” such as Mounjaro and Ozempic is on the rise. However, they present serious risks to ...